Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Veloxis CEO Polvino: How 'Orphan' Tacrolimus Will Beat Astellas Transplant Franchise

This article was originally published in Scrip

Executive Summary

Veloxis Pharmaceuticals A/S has received orphan drug designation from the US FDA for its recently approved extended release tacrolimus product Envarsus XR, a rare achievement for a product which contains a previously approved active ingredient. CEO William Polvino explains to Scrip why the tacrolimus-based Envarsus XR secured orphan drug status, and how it plans to compete with Astellas and its established tacrolimus franchise.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts